author-photo

Melanie E. Dujka

University of Texas MD Anderson Cancer Center

12

Papers

334

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial

2020
Show All
- Source
- Cite
- Save
Citations (0)
Impact of FDG PET Imaging for Expanding Patient Eligibility & Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial

2019 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (6)
in leukemia cells ROS-dependent apoptosis alone and in combination with HDAC inhibitors NPI-0052, a novel proteasome inhibitor, induces caspase-8 and

2010
Show All
- Source
- Cite
- Save
Citations (0)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

2007 Blood
Show All
- Source
- Cite
- Save
Citations (186)
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model

2007 Journal of Cell Biology
Show All
- Source
- Cite
- Save
Citations (0)
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model

2007 Journal of Experimental Medicine
Show All
- Source
- Cite
- Save
Citations (58)
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer : Implications for therapy

2006 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (58)